<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737982</url>
  </required_header>
  <id_info>
    <org_study_id>RBSI14HNVT</org_study_id>
    <nct_id>NCT02737982</nct_id>
  </id_info>
  <brief_title>Sex and Gender Differences in Ischemic Heart Disease - Endocrine Vascular Disease Approach</brief_title>
  <acronym>EVA</acronym>
  <official_title>Sex and Gender Differences in Ischemic Heart Disease: From Bench to Bedside EVA (Endocrine Vascular Disease Approach)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Universities and Research, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of sex-gender medicine is strongly recommended by World Health Organization
      and other international organization. In fact, it is emerging that, although men and women
      are affected to the same cardiovascular diseases (CVD), however they have different risk
      factors, disease progression and response to pharmacological and not-pharmacological
      treatments. Consequentially, the identification of biomarkers and therapeutic approaches
      taking into account sex gender differences (SGD) is relevant to develop a really
      evidence-based medicine.

      With the aim of translate in clinical setting the more recently available basic research
      evidences on estrogens and androgens balance involvement in modulation of
      ischemia-reperfusion myocardial damage, the investigators planned to conduct a research study
      on patients, affected by suspected or known ischemic heart disease (IHD) undergoing
      angiography and/or percutaneous coronary interventions (PCI), aged more than 18 years of both
      sex in ratio 1:1. Thus, in this setting, the goals of this proposal are:

        1. To assess the sex-gender difference in entity of microvascular reperfusion damage in
           patients with IHD undergoing urgent or elective PCI;

        2. To evaluate estrogen/androgen-dependent and -independent effects in gender-related
           differences on myocardial ischemia reperfusion damage occurring during PCI;

        3. To investigate the differences in terms of platelet biology between men and women
           affected by IHD undergoing urgent or elective PCI, matched for age and clinical
           cardiovascular and metabolic characteristics;

        4. To verify sex-driven interplay between response to PCI procedure, platelet function, sex
           hormones and entity of reperfusion and myocardial damage, as well as, the impact on
           clinical outcomes during a 1-year follow up.

      This research study wants to explore and consequently elucidate biological mechanisms
      responsible for sex-based differences in vivo human models of ischemia reperfusion myocardial
      damage. Moreover, the investigators expected to clarify the impact of biological variables
      evaluated on clinical outcomes after reperfusion therapeutic intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Assessment of corrected Thrombolysis In Myocardial Infarction frame count and myocardial blush grade</measure>
    <time_frame>baseline; within 1h from PCI</time_frame>
    <description>angiographic assessment of coronary flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual hormones levels in patients with IHD undergoing PCI</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation and impact of sexual hormones levels in gender-related differences during myocardial reperfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet activation markers including Thromboxane, soluble cluster designation 40 (CD40) Ligand and soluble P-selectin in patients with IHD undergoing PCI</measure>
    <time_frame>baseline; within 1h from PCI; 12 months</time_frame>
    <description>Evaluation of Sex and gender differences in platelet function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes including cardiovascular mortality, re-hospitalization and restenosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular dysfunction assessed by cardiac magnetic resonance</measure>
    <time_frame>7 days from percutaneous coronary intervention</time_frame>
    <description>Among the EVA registry, we plan to perform a pilot study including: patients with stable angina with mono-vessel obstructive coronary artery disease (CAD) undergoing PCI; patients with stable angina undergoing angiography that documented no obstructive coronary disease (with a stenosis &lt;50%) with a impairment of microvascular dysfunction defined during angiography by a myocardial blush grade &lt;2 or coronary flow reserve &lt;2 after stress stimulus.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>IHD Men</arm_group_label>
    <description>Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IHD Women</arm_group_label>
    <description>Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous coronary intervention</intervention_name>
    <description>coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion</description>
    <arm_group_label>IHD Men</arm_group_label>
    <arm_group_label>IHD Women</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women who referred with a suspected IHD to the cath-lab for undergoing percutaneous
        coronary intervention
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with ischemic heart disease (acute or chronic) undergoing percutaneous
             coronary intervention (urgent or elective)

          -  written informed consent

          -  both sex

          -  aged more than 18 years

        Exclusion Criteria:

          -  patients with expectancy of life less than 12 months

          -  active cancer

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeria Raparelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Experimental Medicine Department, Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valeria Raparelli, MD</last_name>
    <phone>+393381603038</phone>
    <email>valeria.raparelli@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefania Basili, MD</last_name>
    <phone>+390649974678</phone>
    <email>stefania.basili@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Umberto I , Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Lenzi, MD</last_name>
      <phone>+39-06-4452391-4469663</phone>
      <email>andrea.lenzi@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Valeria Raparelli, MD</last_name>
      <phone>+393381603038</phone>
      <email>valeria.raparelli@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Valeria Raparelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Lenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Basili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaetano Tanzilli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iacopo Carbone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasquale Pignatelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Isidori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Mangieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Coppola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuliano Bertazzoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Viceconte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Valeria Raparelli</investigator_full_name>
    <investigator_title>University Reseacher</investigator_title>
  </responsible_party>
  <keyword>coronary heart disease</keyword>
  <keyword>gender</keyword>
  <keyword>platelet</keyword>
  <keyword>microvascular dysfunction</keyword>
  <keyword>sexual hormones</keyword>
  <keyword>cardiac magnetic resonance</keyword>
  <keyword>percutaneous coronary interventions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

